4.425
price up icon4.86%   0.205
pre-market  Pre-mercato:  4.32   -0.105   -2.37%
loading
Precedente Chiudi:
$4.22
Aprire:
$4.2426
Volume 24 ore:
20,150
Relative Volume:
0.11
Capitalizzazione di mercato:
$4.42M
Reddito:
$12.99M
Utile/perdita netta:
$-27.95M
Rapporto P/E:
-0.00133
EPS:
-3331.1893
Flusso di cassa netto:
$-26.12M
1 W Prestazione:
-5.25%
1M Prestazione:
-38.28%
6M Prestazione:
-84.64%
1 anno Prestazione:
-99.31%
Intervallo 1D:
Value
$4.23
$4.47
Intervallo di 1 settimana:
Value
$4.22
$4.6699
Portata 52W:
Value
$3.95
$1,299.60

Aptevo Therapeutics Inc Stock (APVO) Company Profile

Name
Nome
Aptevo Therapeutics Inc
Name
Telefono
206-838-0500
Name
Indirizzo
2401 4TH AVE., SEATTLE, WA
Name
Dipendente
37
Name
Cinguettio
@aptevo
Name
Prossima data di guadagno
2026-03-27
Name
Ultimi documenti SEC
Name
APVO's Discussions on Twitter

Compare APVO vs VRTX, REGN, ALNY, ARGX, INSM

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
APVO icon
APVO
Aptevo Therapeutics Inc
4.425 4.42M 12.99M -27.95M -26.12M -3,331.19
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 115.58B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 79.23B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 43.59B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 43.26B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 31.97B 606.42M -1.28B -997.58M -6.403

Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2018-11-05 Iniziato Ladenburg Thalmann Buy
2017-10-05 Ripresa Piper Jaffray Overweight

Aptevo Therapeutics Inc Borsa (APVO) Ultime notizie

pulisher
Mar 23, 2026

APVO Forecast, Price Target & Analyst Ratings | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill

Mar 23, 2026
pulisher
Mar 20, 2026

Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | AP81 | US03835L5049 - marketscreener.com

Mar 20, 2026
pulisher
Mar 20, 2026

Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment - Benzinga

Mar 20, 2026
pulisher
Mar 20, 2026

APVO Stock Price, Quote & Chart | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill

Mar 20, 2026
pulisher
Mar 19, 2026

Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | APVO | US03835L4059 - marketscreener.com

Mar 19, 2026
pulisher
Mar 19, 2026

Aptevo to Participate in March 2026 Conferences - ACCESS Newswire

Mar 19, 2026
pulisher
Mar 19, 2026

Aptevo sends incoming CEO to Roth, spotlights trispecific drugs in Lisbon - Stock Titan

Mar 19, 2026
pulisher
Mar 18, 2026

Hedge Fund Moves: Whats next for Aptevo Therapeutics Inc stock2026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn

Mar 18, 2026
pulisher
Mar 17, 2026

Aptevo Therapeutics implements 1-for-18 reverse stock split - MSN

Mar 17, 2026
pulisher
Mar 17, 2026

Pharma News: Is GeoVax Labs Inc Equity Warrants ROE strong enough2026 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 17, 2026

Aptevo shares drop despite encouraging AML trial results - MSN

Mar 17, 2026
pulisher
Mar 11, 2026

Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate With No CRS in Frontline AML, Promising Safety and Efficacy Data 1 - Minichart

Mar 11, 2026
pulisher
Mar 11, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 11, 2026
pulisher
Mar 11, 2026

Aptevo Reports Promising Interim Data for AML Therapy - TipRanks

Mar 11, 2026
pulisher
Mar 11, 2026

Aptevo Therapeutics: Mipletamig Shows 86% Clinical Benefit Rate with No CRS in Frontline AML - TradingView

Mar 11, 2026
pulisher
Mar 11, 2026

Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine - marketscreener.com

Mar 11, 2026
pulisher
Mar 10, 2026

Aptevo Therapeutics (APVO) reports 86% benefit, no CRS in mipletamig AML data - Stock Titan

Mar 10, 2026
pulisher
Mar 10, 2026

Aptevo Therapeutics (APVO) Reveals Promising Results in AML Tria - GuruFocus

Mar 10, 2026
pulisher
Mar 10, 2026

Aptevo Lists Lower on New Developments - Baystreet.ca

Mar 10, 2026
pulisher
Mar 10, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Mar 10, 2026
pulisher
Mar 10, 2026

Aptevo Therapeutics stock tumbles despite positive trial data - Investing.com India

Mar 10, 2026
pulisher
Mar 10, 2026

Aptevo Therapeutics stock tumbles despite positive trial data By Investing.com - Investing.com UK

Mar 10, 2026
pulisher
Mar 10, 2026

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Bitget

Mar 10, 2026
pulisher
Mar 08, 2026

Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort - MSN

Mar 08, 2026
pulisher
Mar 07, 2026

Panic Selling: Is Aptevo Therapeutics Inc stock trending bullishQuarterly Investment Review & Daily Price Action Insights - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 03, 2026

10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm

Mar 03, 2026
pulisher
Mar 02, 2026

APVO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 02, 2026
pulisher
Feb 28, 2026

Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen - Defense World

Feb 28, 2026
pulisher
Feb 25, 2026

Retail Surge: Can Moodys Corporation reach resistance levels soon2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn

Feb 25, 2026
pulisher
Feb 25, 2026

APVO SEC FilingsAptevo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Feb 25, 2026
pulisher
Feb 22, 2026

APVOAptevo Therapeutics Inc Latest Stock News & Market Updates - Stock Titan

Feb 22, 2026
pulisher
Feb 20, 2026

Aptevo Therapeutics Inc expected to post a loss of $8.10 a shareEarnings Preview - TradingView

Feb 20, 2026
pulisher
Feb 19, 2026

Aptevo Therapeutics Shareholders Approve Expanded Equity Financing Capacity - TipRanks

Feb 19, 2026
pulisher
Feb 18, 2026

Aptevo Therapeutics (NASDAQ: APVO) clears shareholder approval for large Yorkville equity issuance - Stock Titan

Feb 18, 2026
pulisher
Feb 17, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Feb 17, 2026
pulisher
Feb 16, 2026

Seattle biotech CEO to step down, replacement named - The Business Journals

Feb 16, 2026
pulisher
Feb 16, 2026

Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Intellectia AI

Feb 16, 2026
pulisher
Feb 16, 2026

Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Drop in Short Interest - Defense World

Feb 16, 2026
pulisher
Feb 15, 2026

Will Aptevo Therapeutics Inc. stock remain a Wall Street favorite2025 Performance Recap & Long-Term Investment Growth Plans - mfd.ru

Feb 15, 2026
pulisher
Feb 14, 2026

Will Aptevo Therapeutics Inc. be affected by tariffsCPI Data & AI Based Buy and Sell Signals - mfd.ru

Feb 14, 2026
pulisher
Feb 13, 2026

Can Aptevo Therapeutics Inc. navigate macro headwindsJuly 2025 News Drivers & Technical Buy Zone Confirmation - mfd.ru

Feb 13, 2026
pulisher
Feb 12, 2026

What is Aptevo Therapeutics Inc.’s valuation compared to sectorM&A Rumor & Accurate Entry/Exit Alerts - mfd.ru

Feb 12, 2026
pulisher
Feb 12, 2026

Why Aptevo Therapeutics Inc. stock attracts high net worth investorsProduct Launch & Real-Time Market Sentiment Alerts - mfd.ru

Feb 12, 2026
pulisher
Feb 11, 2026

Is Aptevo Therapeutics Inc. stock a value trapQuarterly Portfolio Review & Scalable Portfolio Growth Ideas - mfd.ru

Feb 11, 2026
pulisher
Feb 10, 2026

Aug Rallies: What is Aptevo Therapeutics Inc. s 5 year growth outlookJuly 2025 Setups & Verified Entry Point Detection - mfd.ru

Feb 10, 2026
pulisher
Feb 05, 2026

Risk Report: Is Aptevo Therapeutics Inc impacted by rising ratesChart Signals & Safe Swing Trade Setups - baoquankhu1.vn

Feb 05, 2026
pulisher
Feb 04, 2026

Is Aptevo Therapeutics Inc. stock a top momentum playSell Signal & Reliable Entry Point Alerts - mfd.ru

Feb 04, 2026
pulisher
Feb 04, 2026

Aptevo Therapeutics Announces CEO Transition and Leadership Changes - The Globe and Mail

Feb 04, 2026
pulisher
Feb 03, 2026

Aptevo Therapeutics announces leadership changes as CEO retires By Investing.com - Investing.com Canada

Feb 03, 2026
pulisher
Feb 03, 2026

Aptevo Announces CEO Changes - marketscreener.com

Feb 03, 2026
pulisher
Feb 03, 2026

Aptevo Therapeutics Inc. Announces Board and Executive Changes - marketscreener.com

Feb 03, 2026

Aptevo Therapeutics Inc Azioni (APVO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
Capitalizzazione:     |  Volume (24 ore):